Shengfang Jin, Ensem Therapeutics president and CEO

BeiGene li­cens­es CDK2 in­hibitor from En­sem in po­ten­tial $1.33B deal

BeiGene has struck a deal with En­sem Ther­a­peu­tics to li­cense an oral cy­clin-de­pen­dent ki­nase 2 (CDK2) in­hibitor in ex­change for an undis­closed up­front pay­ment and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.